A closer look at hepatitis C clearance in HIV controllers: a responseASHER, Alice K; SANTOS, Glenn-Milo; PAGE, Kimbely et al.AIDS (London). 2014, Vol 28, Num 8, pp 1241-1242, issn 0269-9370, 2 p.Article

Reactivation of hepatitis B virus infection associated with maraviroc use in an HIV-infected patientSIEGEL, Marc O.AIDS (London). 2014, Vol 28, Num 7, pp 1079-1080, issn 0269-9370, 2 p.Article

Telaprevir therapy, renal impairment, and their effects on the pharmacokinetics of tenofovir in HIV/hepatitis C virus coinfected patientsGERVASON, Cristina; MILAZZO, Laura; PEZZANI, Diletta et al.AIDS (London). 2014, Vol 28, Num 2, pp 285-287, issn 0269-9370, 3 p.Article

Treatment of pediatric chronic viral hepatitis B and CHIERRO, L; FISCHLER, B.Clinics and research in hepatology and gastroenterology (Print). 2014, Vol 38, Num 4, pp 415-418, issn 2210-7401, 4 p.Article

Hépatite C: la solution à 100 % ? = Hepatitis C: the 100% solution?PARIENTE, Alexandre.La Revue du praticien (Paris). 2014, Vol 64, Num 2, issn 0035-2640, S1-S2, SUPArticle

Siméprévir pour traiter l'hépatite C = Simeprevir (Olysio) for Chronic Hepatitis CThe Medical letter on drugs and therapeutics (Edition française). 2014, Vol 36, Num 3, pp 9-11, issn 0253-8512, 3 p.Article

Does HIV Remain a Risk Factor for Achieving Sustained Virologic Response Under Direct Acting Antiviral-Based Modern Hepatitis C Virus Therapy?ROCKSTROH, Jürgen Kurt.Clinical infectious diseases. 2014, Vol 59, Num 12, pp 1777-1778, issn 1058-4838, 2 p.Article

Paritaprévir avec ritonavir, ombitasvir, dasabuvir et ribavirine dans l'hépatite chronique C de génotype 1 avec cirrhose = Paritaprevir with ritonavir ombitasvir, dasabuvir and ribavirin in chronic hepatitis C genotype 1 with cirrhosisPARIENTE, Alexandre.La Revue du praticien (Paris). 2014, Vol 64, Num 9, issn 0035-2640, S1-S2, SUPArticle

Analysis of the transcriptome and immune function of monocytes during IFNα-based therapy in chronic HCV revealed induction of TLR7 responsivenessJUN HOU; GROOTHUISMINK, Zwier M. A; LUDI KONING et al.Antiviral research. 2014, Vol 109, pp 116-124, issn 0166-3542, 9 p.Article

Assessing the feasibility of hepatitis C virus vaccine trials: Results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness studyWHITE, Bethany; MADDEN, Annie; PRINS, Maria et al.Vaccine. 2014, Vol 32, Num 42, pp 5460-5467, issn 0264-410X, 8 p.Article

Baseline Hepatitis C Virus (HCV) NS3 Polymorphisms and Their Impact on Treatment Response in Clinical Studies of the HCV NS3 Protease Inhibitor FaldaprevirBERGER, Kristi L; TRIKI, Ibtissem; KUKOLJ, George et al.Antimicrobial agents and chemotherapy. 2014, Vol 58, Num 2, pp 698-705, issn 0066-4804, 8 p.Article

Benzimidazole derivative, BM601, a novel inhibitor of hepatitis B virus and HBsAg secretionXU, Yi-Bin; LI YANG; WEI TANG et al.Antiviral research. 2014, Vol 107, pp 6-15, issn 0166-3542, 10 p.Article

Causes of Death and Characteristics of Decedents With Viral Hepatitis, United States, 2010LY, Kathleen N; JIAN XING; KLEVENS, R. Monina et al.Clinical infectious diseases. 2014, Vol 58, Num 1, pp 40-49, issn 1058-4838, 10 p.Article

Chronic Hepatitis C in the Aged: Much Ado About Nothing or Nothing to Do?MALNICK, Stephen; MAOR, Yaakov; MELZER, Ehud et al.Drugs & aging. 2014, Vol 31, Num 5, pp 339-347, issn 1170-229X, 9 p.Article

Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional studyMARCELLIN, Patrick; ARAMA, Victoria; MORAIS, Edith et al.Antiviral therapy (London). 2014, Vol 19, Num 3, pp 235-243, issn 1359-6535, 9 p.Article

Cost-effectiveness Analysis of the National Perinatal Hepatitis B Prevention ProgramBARBOSA, Carolina; SMITH, Emily A; HOERGER, Thomas J et al.Pediatrics (Evanston). 2014, Vol 133, Num 2, pp 243-253, issn 0031-4005, 11 p.Article

Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infectionSAAB, S; GORDON, S. C; PARK, H et al.Alimentary pharmacology & therapeutics. 2014, Vol 40, Num 6, pp 657-675, issn 0269-2813, 19 p.Article

Effects of hepatitis B immunization on prevention of mother-to-infant transmission of hepatitis B virus and on the immune response of infants towards hepatitis B vaccineLEI ZHANG; GUI, Xi-En; TETER, Caroline et al.Vaccine. 2014, Vol 32, Num 46, pp 6091-6097, issn 0264-410X, 7 p.Article

Entry inhibitors and future treatment of hepatitis CFOFANA, Isabel; JILG, Nikolaus; CHUNG, Raymond T et al.Antiviral research. 2014, Vol 104, pp 136-142, issn 0166-3542, 7 p.Article

Estimating the prevalence of hepatitis C infection in New York City using surveillance dataBALTER, S; STARK, J. H; KENNEDY, J et al.Epidemiology and infection. 2014, Vol 142, Num 2, pp 262-269, issn 0950-2688, 8 p.Article

Hepatic Decompensation in Antiretrovirai-Treated Patients Co-infected With HIV and Hepatitis C Virus Compared With Hepatitis C Virus— Monoinfected Patients: A Cohort StudyLO RE, Vincent; KALLAN, Michael J; GIBERT, Cynthia L et al.Annals of internal medicine. 2014, Vol 160, Num 6, pp 369-379, issn 0003-4819, 11 p.Article

Hepatitis B Testing and Vaccination Among Adults With Sexually Transmitted Infections in a Large Managed Care OrganizationHECHTER, Rulin C; JACOBSEN, Steven J; YI LUO et al.Clinical infectious diseases. 2014, Vol 58, Num 12, pp 1739-1745, issn 1058-4838, 7 p.Article

Hepatitis B vaccination coverage rates among adults in rural China: Are economic barriers relevant?DAWEI ZHU; JIAN WANG; WANGEN, Knut Reidar et al.Vaccine. 2014, Vol 32, Num 49, pp 6705-6710, issn 0264-410X, 6 p.Article

Hepatitis C in HIV-Infected Patients: Impact of Direct-Acting AntiviralsBICHOUPAN, Kian; DIETERICH, Douglas T.Drugs (Basel). 2014, Vol 74, Num 9, pp 951-961, issn 0012-6667, 11 p.Article

Hepatitis C virus polymerase―polymerase contact interface: Significance for virus replication and antiviral designLOPEZ-JIMENEZ, Alberto José; CLEMENTE-CASARES, Pilar; SABARIEGOS, Rosario et al.Antiviral research. 2014, Vol 108, pp 14-24, issn 0166-3542, 11 p.Article